VasoStitch Inc.
Access and closure systems for minimally invasive valve replacement and repair
This article was originally published in Start Up
Executive Summary
Delivering valve devices to a structurally damaged heart through the femoral artery can be a tricky proposition. Cardiologists normally gain access through a large incision and employ balloons to increase the diameter of the aperture. Problems can arise when trying to close the hole at the end of the procedure. New technology from VasoStitch Inc. allows for simpler and safer access and closure of catheter-based interventions for minimally invasive valve replacement and repair. The start-up’s two devices, yet to be branded, are for accessing the heart through the femoral artery (transfemorally) and the chest wall (transapically), respectively
You may also be interested in...
Amir Belson: Stealth Medtech Entrepreneur
Amir Belson is among the most prolific device entrepreneurs in the industry today, having launched a dozen companies in the past 12 years. Not as well-known as other physician-inventors, he combines an aggressive IP strategy with an innovative approach to early-stage financing to launch companies in a variety of clinical spaces.
ZipLine Medical Inc.
For many years, non-absorbable and absorbable sutures and staples have been the primary method of closing the external skin layer. Both types of devices provide good incision closure to promote wound healing, but they have drawbacks. There hasn't been much innovation in incision closure over the last decade, but now, innovative companies are working to address concerns with the gold standards. ZipLine Medical Inc. hopes to be at the forefront of this evolution with a noninvasive, external skin closure system intended as an alternative to sutures and staples that decreases operating time, heals the wound in a uniform manner with minimum skin stress and a much-improved aesthetic result and is easily removed by the patient at home.
Big Pharma CEOs Suggest Policy Changes As They Return To Beijing
Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.